Study of the Clinical Features of Autoimmune Hepatitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02994537|
Recruitment Status : Recruiting
First Posted : December 16, 2016
Last Update Posted : November 24, 2020
|Condition or disease||Intervention/treatment|
|Hepatitis, Autoimmune||Other: Different biochemical results or pathogenesis.|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Study of the Clinical Features of Autoimmune Hepatitis|
|Study Start Date :||October 2013|
|Estimated Primary Completion Date :||June 1, 2022|
|Estimated Study Completion Date :||December 31, 2022|
acute autoimmune hepatitis
Patients diagnosed autoimmune hepatitis(AIH) are divided into acute cohort or chronic cohort (acute-on-chronic and chronic were all included)by biochemical results, such as liver function and coagulation, then the investigators will compare the histological results, treatment effects and prognosis between the two groups. Further more, the investigators will study the pathogenesis of different forms of autoimmune hepatitis. Even more, the investigators want to explore drug induced AIH and viral hepatitis related AIH.
Other: Different biochemical results or pathogenesis.
Comparing the pathogenesis,clinical characteristics and treatment effects between the acute autoimmune hepatitis group and the chronic autoimmune hepatitis group. The investigators don't use special intervention.
- Biochemical remission of participants [ Time Frame: 3 years after standard immunosuppressive treatment. ]This study is now in the phase 1, and the outcome at phase 1 is the biochemical remission of AIH patients. In details, if the participants' serum ALT,AST and IgG returned to normal, that means this participant reached the biochemical remission.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02994537
|Contact: Li Yang, MD||+86 firstname.lastname@example.org|
|Contact: Yi Shen, MD||+86 18280097412 ext email@example.com|
|Division of Gastroenterology & Hepatology,West China Hospital,Sichuan University||Recruiting|
|Chengdu, Sichuan, China, 610041|
|Contact: Li Yang, MD +86 18980601276 firstname.lastname@example.org|
|Contact: Yi Shen, MM +86 18280097412 email@example.com|
|Principal Investigator: Yi Shen, MM|
|Study Director:||Li Yang, MD||Division of Gastroenterology & Hepatology,West China Hospital,Sichuan University|